The efficacy of BIIBO59 in patients with cutaneous lupus erythematosus with and without concomitant systemic lupus erythematosus during 16 weeks was evaluated.
At AAD VMX 2021, researchers presented data on skin clearance rates through 5 years with guselkumab in patients with moderate to severe plaque psoriasis.
The investigators reported efficacy results from the MAXIMISE trial, the first randomized controlled trial evaluating the efficacy of a biologic agent in the treatment of axial manifestations in PsA.
Pooled data analyses on efficacy, safety, and 1-year follow-up on the use of tirbanibulin for the treatment of actinic keratosis lesions was presented at the AAD VMX 2021.
The influence of Vichy volcanic mineralizing water and hyaluronic acid treatment on rosacea was presented at the American Academy of Dermatology’s Virtual Meeting Experience (AAD VMX) 2021.
The latest data on the safety and efficacy of roflumilast foam for scalp and body psoriasis was presented at the American Academy of Dermatology’s Virtual Meeting Experience (AAD VMX) 2021.
Researchers compared the safety and efficacy of treatment with deucravacitinib vs placebo and apremilast in patients with moderate to severe plaque psoriasis.
Researchers at the AAD vmx 2021 describe the efficacy of ruxolitinib cream for atopic dermatitis based on baseline clinical characteristics using data from 2 studies.
Researchers sought to determine whether there were any clinically meaningful improvements in AD signs, symptoms, and quality of life in pediatric patients treated with different doses of dupilumab.